Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 4/20 | 0.43 |
| ▸ | EDNRA | P25101 | 4/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.41 |
| ▸ | RXRG | P48443 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6595450 | 0.84 | CCR2 (0.50) | EDNRBEDNRAS1PR5MRGPRX4S1PR1 | |
| SCHEMBL7082978 | 0.83 | AR (0.41) | ALOX5AP | |
| SCHEMBL27585995 | 0.78 | ALOX5AP (0.41) | EDNRBEDNRAPTGER1ALOX5APRXRA | |
| SCHEMBL7083186 | 0.78 | MAPT (0.43) | PTGER1ALOX5APRXRARXRBRXRG | |
| SCHEMBL5839009 | 0.69 | RXRA (0.55) | RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL8697539 | 0.68 | SERPINE1 (0.38) | — | |
| SCHEMBL7089675 | 0.68 | ABCB11 (0.48) | EDNRBEDNRAALOX5AP | |
| SCHEMBL6780034 | 0.65 | CCR2 (0.61) | EDNRBEDNRA | |
| SCHEMBL8697038 | 0.64 | SERPINE1 (0.40) | EDNRBEDNRA | |
| SCHEMBL6597658 | 0.64 | ABCB11 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| EP-1252142-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001051466-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | CCR2, CCR1, CCR5 | EDNRB 176/4885EDNRA 155/4885PTGER1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.